| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00974922 Details | 2018-03-09 Interventional | 4 | 40 | Aliskiren Cholecalciferol Vitamin D Hypertension Vitamin D Defic… | Administrative/Sponsor Business Decision - terminated - study was not completed Study was never completed due to early termination of the trial by sponsor. Data were never analyzed because group assignment was never un-blinded and data lacked any scientific utility. | |||
| NCT00096265 Details | 2018-03-09 Interventional | 3 | 126 | Erlotinib Hydro… Temozolomide Brain Neoplasms Carcinoma, Non-… Lung Neoplasms Neoplasms Metastatic Mali… Recurrent Non-S… Stage IV Non-Sm… | - This study stopped accrual early due to unmet targeted accrual goals with 126 subjects accrued out of 381 planned. | |||
| NCT03456401 2014-001956-52 Details | 2018-03-07 Interventional | 2 | 18 | Sorafenib Sunitinib Kidney Neoplasm… Renal Cancer Ce… | availability of new and more promising therapeutic agents than expected in the experimentation
in question - | |||
| NCT03329547 Details | 2018-03-07 Interventional | 1 | 0 | Cefixime Bacterial Infec… Infections, Bac… | Change in commercial strategy - | |||
| NCT03239600 Details | 2018-03-07 Interventional | 2 | 0 | Methotrexate Autoimmune Dise… Sjogren's Syndr… | The study is stopped for Portfolio prioritization. - | |||
| NCT02354768 Details | 2018-03-07 Interventional | 3 | 19 | Antidiarrheals Lanreotide Loperamide High Output Sto… | - - | |||
| NCT01659099 Details | 2018-03-07 Interventional | 3 | 671 | Bleomycin Cyclophosphamid… Doxorubicin Obinutuzumab Prednisone Rituximab Vincristine Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Diffuse Large B… | experimental treatment not Superior to standard - no need to continue the follow-up - | |||
| NCT01313611 Details | 2018-03-07 Interventional | 2 | 62 | Bendamustine Hy… Rituximab Lymphoma Lymphoma, Folli… Follicular Lymp… | Treament with rituximab during maintenance phase was stoped, according to DSMC recommendations,
since 3 cases of deaths occured. - | |||
| NCT03347994 Details | 2018-03-06 Interventional | 1 | 0 | 14-O-phosphonoo… Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | Discordance in contractual language and terms. - | |||
| NCT02503176 Details | 2018-03-05 Interventional | 3 | - | Ophthalmic Solu… Dry Eye Syndrom… Keratoconjuncti… Sjogren's Syndr… Syndrome Dry Eye With Sj… | Discontinuation of the development - | |||
| NCT03183492 Details | 2018-03-02 Interventional | 4 | 0 | Vaccines Hepatitis Hepatitis A | Sponsor cancelled the study as real life impact data has already shown the value of HepA
vaccination & as no critical need to gather additional data in Israel. - | |||
| NCT02395783 Details | 2018-03-02 Interventional | 2/3 | 14 | Melatonin Brain Injuries Leukoencephalop… Premature Birth | - - | |||
| NCT01627379 2010-020606-15 Details | 2018-03-02 Interventional | 3 | - | Panitumumab Carcinoma, Squa… Esophageal Squa… Neoplasms, Squa… Esophageal Squa… | Sponsor decision due to recommendation of the IDMC. - | |||
| NCT01610570 Details | 2018-03-02 Interventional | 1/2 | [1 Refs] | 8 | Plicamycin Sarcoma Sarcoma, Ewing Ewing Sarcoma | Study was closed to enrollment before dose level one was completed. - | ||
| NCT03220867 Details | 2018-02-28 Interventional | 1 | 0 | Risperidone Healthy | CFDA announced Xi'An Risperdal as reference drug, no need for this BE trial from both
scientific and ethical perspective. - | |||
| NCT02590003 Details | 2018-02-28 Interventional | 2 | 3 | Carboplatin Paclitaxel Carcinoma, Non-… Carcinoma, Non-… | Trial was stopped after non-response to treatment. - | |||
| NCT02374567 Details | 2018-02-28 Interventional | 3 | 407 | Acamprosate Agomelatine Alprazolam Amisulpride Amitriptyline Aripiprazole Benperidol Biperiden Bromazepam Bromperidol Brotizolam Bupropion Buspirone Carbamazepine Chloral Hydrate Chlormethiazole Chlorprothixene Citalopram Clobazam Clomipramine Clonazepam Clopenthixol Clozapine Diazepam Diphenhydramine Donepezil Doxepin Duloxetine Hydr… Escitalopram Fluoxetine Flupenthixol Flupenthixol de… Fluphenazine Fluphenazine de… Fluphenazine en… Flurazepam Fluspirilene Fluvoxamine Gabapentin Galantamine Haloperidol Hydroxyzine Imipramine Lacosamide Lamotrigine Levetiracetam Lorazepam Lormetazepam Maprotiline Melatonin Memantine Methotrimeprazi… Mianserin Midazolam Mirtazapine Moclobemide Nicergoline Nitrazepam Nortriptyline Olanzapine Opipramol Oxazepam Oxcarbazepine Paliperidone Pa… Paroxetine Perazine Perphenazine Phenobarbital Phenytoin Pimozide Pipamperone Piracetam Pregabalin Promethazine Quetiapine Fuma… Reboxetine Risperidone Rivastigmine Sertindole Sertraline Sulpiride Temazepam Thioridazine Tiapride Hydroc… Topiramate Tranylcypromine Trazodone Triazolam Trimipramine Valproic Acid Venlafaxine Hyd… Zaleplon Ziprasidone Zolpidem Zopiclone Anxiety Disorde… Psychophysiolog… Schizophrenia Somatoform Diso… Dementia Depression Psychosomatic D… | - - | |||
| NCT02198482 2014-000477-39 Details | 2018-02-28 Interventional | 2 | 6 | Cytarabine Daunorubicin Mitoxantrone Leukemia Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Preleukemia Syndrome Acute Myeloid L… High-risk Myelo… | development program of study drug volasertib was stopped by Boehringer Ingelheim due to
manufacturing problems - | |||
| NCT03307603 Details | 2018-02-27 Interventional | 1/2 | 0 | Nivolumab Colorectal Neop… Metastatic Colo… | Sponsor chose not to continue - | |||
| NCT02342353 Details | 2018-02-27 Interventional | 1 | 8 | Erlotinib Hydro… Carcinoma, Non-… Lung Neoplasms Non-Small Cell … Nonsmall Cell L… | Drug shortage - |